CMO Rock Edwin buys 305,000 GLYC shares in 2 transactions (June 20-21) at $0.26 blended avg, stock down 90.6% in 90 days
Rock Edwin, Chief Medical Officer of GlycoMimetics, purchased 305,000 shares across two separate transactions on June 20-21, 2024, for a combined $78,824.50 at a blended average price of $0.26, expanding his holdings by 81.2%. This comes against a backdrop of severe deterioration: the stock has declined 90.6% over the past 90 days and currently trades at $26.66, down 92.4% from its 52-week high of $349.00. Fundamental conditions are dire, with the company reporting quarterly revenue of $75,000.00 while generating a net loss of $10,736,667.00, and annual revenue contracted 86.7% year-over-year. Notably, Edwin's own prior transaction history at this ticker shows he bought twice in September 2023, both timing well at the 90-day horizon with gains exceeding 9000%, suggesting an established pattern of accumulation at depressed moments; however, his current purchase occurs against far steeper recent losses and into a company with severe revenue collapse and persistent unprofitability, presenting a markedly different risk context than his prior buys.